77 results
Page 2 of 4
6-K
EX-99.1
vjvopeis6idd19 o8i
5 Oct 21
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
12:34pm
F-3
ogda73d44xvt66 znk2
21 Sep 21
Shelf registration (foreign)
12:50pm
6-K
EX-99.1
0n1wrs8 0w7m
21 Sep 21
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
9:42am
6-K
EX-99.1
ylx x36kme
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
6-K
EX-99.1
sbu 2wzf8t4k8ge4
30 Jul 21
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
10:09am
6-K
EX-99.1
5tfkjngxy uou
26 Jul 21
Current report (foreign)
11:47am
6-K
EX-99.1
3lq6879fsem
29 Jun 21
Current report (foreign)
8:18am
6-K
EX-99.1
1xej jevyjvg01ops
26 May 21
Live webcast of the Shareholders’ Meeting
9:55am
6-K
EX-99.1
1hoj72p7po e4b3b
7 May 21
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
6:13am
424B5
9yunuefb7tn aa0p
5 May 21
Prospectus supplement for primary offering
4:50pm
6-K
EX-99.1
71n8ufi1b14vv l80axh
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
424B5
mlu66t6qby6o85h2g12
3 May 21
Prospectus supplement for primary offering
5:14pm
6-K
EX-99.2
e5n9apb s4sihz4l
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
EX-99.1
kbemp2s1miifncm oytd
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
EX-99.1
eqwcxfjradgjz
21 Apr 21
ERYTECH Requested a Pre-BLA Meeting with the FDA
8:01am
6-K
EX-99.1
ex6duopt
19 Apr 21
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of
9:48am
6-K
EX-99.1
jqmsbwzre1t0icyt
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
6-K
EX-99.1
8amtz5d8z4 z1sll
8 Feb 21
ERYTECH Announces TRYbeCA-1 Phase 3 Trial
9:15am
6-K
EX-99.1
vx17gb
27 Jan 21
ERYTECH Highlights 2021 Milestones
10:17am